**Guideline Page and Request** | **Panel Discussion** | **References** | **Vote**  
--- | --- | --- | ---  
Internal request; HODG-2 and HODG-4: Review level of evidence for ABVD. | Based on the data in the noted reference, the panel consensus was to change the category recommendation for combined modality therapy with ABVD + RT from a category 2A to category 1 for patients with stage I A, IIA favorable disease and stage I-II Unfavorable (bulky) disease. | Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD 11 trial. J Clin Oncol 2010;28:4199-4206. | YES 17 | NO 0 | ABSTAIN 0  
Internal request; HODG-4, HODG-7, HODG-8, HODG-9: Consider adding BEACOPP + ABVD + RT | Based on the data in the noted reference and panel consensus, the regimen BEACOPP + ABVD + RT was added as a treatment option for patients with stage I-II Unfavorable disease (non bulky or bulky). | von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s Lymphoma: Final analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol 2012;30:907-913. | YES 17 | NO 0 | ABSTAIN 0  
Internal request; HODG-14: Consider removing single agent rituximab as a treatment option. | The panel consensus was to remove single agent rituximab as a treatment option for patients with clinical stage IB, IIB, III, IV lymphocyte-predominant Hodgkin lymphoma, either as initial therapy or maintenance therapy. The progression free survival (PFS) is better with combined modality therapy, when compared to single agent rituximab. | • Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-4365.  